GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

The nearly 40-year-old law that created the Vaccine Injury Compensation Program has received a lot of attention this month.

Hengrui Pharmaceuticals Co. Ltd. is out-licensing to GSK plc its potential best-in-class phase I phosphodiesterase 3 and 4 inhibitor (HRS-9821) for treating chronic obstructive pulmonary disease along ...

Hengrui Pharma partners with GSK to develop 12 innovative medicines, enhancing COPD treatment and expanding global growth ...

Find insight on AstraZeneca, Philips, EssilorLuxottica and more in the latest Market Talks covering Health Care.

GSK has signed a $500 million upfront licensing deal with Jiangsu Hengrui to secure global rights to its COPD drug HRS‑9821 ...

London: GSK plc has announced it has entered into agreements with Hengrui Pharma (600276.SH; 01276.HK) to develop up to 12 ...

Hengrui Pharma enters agreement and with GSK to develop up to 12 innovative medicines across respiratory, immunology & inflammation & oncology: Jiangsu, China Tuesday, July 29, 20 ...

Pharma giant Glaxosmithkline, which has major operations in Upper Providence and West Point, is partnering with China-based ...

Relief over a US-EU trade deal today benefited the FTSE 100 index in a session when leading European benchmarks rose by as ...

Jiangsu Hengrui Pharmaceuticals' shares surged 10% to a 4-year high after licensing HRS-9821 and 11 programs to ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...